SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen, Inc. – BIIB

NEW YORK, NY / ACCESSWIRE / July 24, 2015 / Pomerantz LLP is investigating claims on behalf of investors of Biogen (“Biogen” or the “Company”) (NASDAQ: BIIB). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

The investigation concerns whether Biogen and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

On July 24, 2015, pre-market, Biogen reported Q2 2015 results and updated its full-year financial guidance from 14-16% to 6-8% above 2014 revenues. The Company also announced that sales of the company’s multiple-sclerosis drug tecfidera have slowed on safety concerns following last year’s report of the death of a tecfidera patient.

On this news, Biogen shares have dropped as much as 74.34, or 19.31%, on intraday trading on July 24, 2015.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Florida, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz, LLP

ReleaseID: 430820